Voluntary Licensing Agreement for New-Generation Cancer Medicine Broadens Patient Access in Morocco and Egypt
In what is a significant milestone in broadening the availability of cancer treatments in Morocco and Egypt, biopharmaceutical manufacturer Novartis recently established a voluntary licensing agreement with the Medicines Patent Pool (MPP) to increase patient access to a medicine used to treat chronic myeloid leukemia (CML).
As the COVID-19 pandemic continues to impact patients globally, clinical researchers throughout the Middle East and North Africa are rapidly testing investigational medicines and vaccine candidates in clinical trials. These trials are vital to determining the impact a potential new treatment may have on patients, while providing necessary insights to drive promising COVID-19 therapies forward in a quick, safe and efficient manner.
Egypt has the largest patient population in the Middle East and North Africa and plays an increasingly pivotal role in the research, development and manufacturing of new medicines. The country hosts more clinical trials for new treatments than any other in the region.